Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, Phase 3 trial

Tina Vilsbøll; Ella Ekholm; Eva Johnsson; Ricardo Garcia‐Sanchez; Nalina Dronamraju; Serge A. Jabbour; Marcus Lind

doi:10.1111/dom.13981

Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, Phase 3 trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.13981 ◽

2020 ◽

Vol 22 (6) ◽

pp. 957-968

Author(s):

Tina Vilsbøll ◽

Ella Ekholm ◽

Eva Johnsson ◽

Ricardo Garcia‐Sanchez ◽

Nalina Dronamraju ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Decision letter for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

10.1111/dom.13981/v1/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

10.1111/dom.13981/v1/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Author response for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

10.1111/dom.13981/v2/response1 ◽

2020 ◽

Author(s):

Tina Vilsbøll ◽

Ella Ekholm ◽

Eva Johnsson ◽

Ricardo Garcia‐Sanchez ◽

Nalina Dronamraju ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Author Response ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

10.1111/dom.13981/v1/review3 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

10.1111/dom.13981/v2/review1 ◽

2020 ◽

Author(s):

Afshin Salsali

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Decision letter for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

10.1111/dom.13981/v2/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Review for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

10.1111/dom.13981/v1/review2 ◽

2019 ◽

Author(s):

Iouri Bachmakov

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Parallel Design ◽

Open Label Phase

Download Full-text

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

The Lancet ◽

10.1016/s0140-6736(15)60936-9 ◽

2015 ◽

Vol 385 (9982) ◽

pp. 2057-2066 ◽

Cited By ~ 122

Author(s):

Lawrence Blonde ◽

Johan Jendle ◽

Jorge Gross ◽

Vincent Woo ◽

Honghua Jiang ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Insulin Lispro ◽

Open Label ◽

Phase 3 ◽

Prandial Insulin ◽

Open Label Phase

Download Full-text

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in J apanese patients with type 2 diabetes: a randomized, open‐label, phase III , non‐inferiority study

Diabetes Obesity and Metabolism ◽

10.1111/dom.12540 ◽

2015 ◽

Vol 17 (10) ◽

pp. 994-1002 ◽

Cited By ~ 50

Author(s):

E. Araki ◽

N. Inagaki ◽

Y. Tanizawa ◽

T. Oura ◽

M. Takeuchi ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Once Daily ◽

Daily Insulin ◽

Open Label Phase

Download Full-text

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(13)70013-5 ◽

2013 ◽

Vol 1 (2) ◽

pp. 123-131 ◽

Cited By ~ 23

Author(s):

Bernard Zinman ◽

J Hans DeVries ◽

Bruce Bode ◽

David Russell-Jones ◽

Lawrence A Leiter ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Insulin Degludec ◽

Treat To Target ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Two Phase

Download Full-text